

Clinical Policy Title:	varenicline
Policy Number:	RxA.707
Drug(s) Applied:	Tyrvaya™
Original Policy Date:	12/07/2021
Last Review Date:	03/01/2024
Line of Business Policy Applies to:	All Line of Business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Dry eye disease (must meet all):

1. Diagnosis of DED (Dry eye disease);
2. Trial and failure of Restasis® AND Xiidra®, unless contraindicated or clinically significant adverse effects are experienced;

Prescribed by or in consultation with an ophthalmologist;

Approval Duration

Commercial: 12 months

Medicaid: 12 months

II. Continued Therapy Approval

A. Dry eye disease (must meet all):

1. Member is currently receiving or has been treated with this medication within the past 90 days, excluding manufacturer samples.

Approval Duration

All Lines of Business (except Medicare): 12 months

References

1. American Academy of Ophthalmology Cornea/External Disease Committee. Preferred Practice Pattern® Guidelines. Dry Eye Syndrome. Chicago, IL: American Academy of Ophthalmology; November 2018. Available at: www.aao.org/ppp. Accessed September 5, 2022.

Review/Revision History	Review/Revision Date	P&T Approval Date
-------------------------	----------------------	-------------------

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

Policy established.	10/26/2021	12/07/2021
Policy was reviewed: 1. Continued Therapy Approval Criteria II.A.1 was rephrased to "Member is currently receiving medication that has been authorized by RxAdvance...". 2. References were reviewed and updated.	9/5/2022	10/19/2022
Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed 1. Removed age and dosing restriction 2. Updated approval duration from 1 month to 12 months 3. Removed T/F of OTC lubricants 4. Changed from SSE to DSE	3/1/2024	2/28/2024